Search Results

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services.

Vitrolife AB entered into a definitive agreement to acquire 100% of the shares in Igenomix S.L.[1] from EQT and other shareholders.

As announced on 30 November, 2021 , Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022.

Igenomix, a leading reproductive and fertility bio-tech company, launched today their FDA-EUA approved COVID-19 RT-PCR Test in an effort to combat the impact of the current pandemic. This test, already available, combined with a COVID-19 Antibody Test, will make up the Igenomix Biological Passport, a service that will allow for organizations

Sales amounted to SEK 406 (320) million, corresponding to an increase of 27 percent in SEK. Sales increased by 30 percent in local currency.

Sales amounted to SEK 382 (209) million, corresponding to an increase of 83 percent in SEK. Sales increased by 94 percent in local currency.

With this incorporation, the company now has a total of 23 reproductive genetics laboratories worldwide

Collaboration aims to identify novel targets and disease mechanisms in infertility and pregnancy-related conditions, with the goal of developing innovative diagnostic and therapeutic strategies

Vitrolife AB publishes a prospectus for the admission to trading of newly issued shares in Vitrolife on Nasdaq Stockholm’s main market in connection with a non-cash issue through which Vitrolife acquires all shares in Mendel Holdco S.L. and thereby indirectly all shares in Igenomix S.L.

This collaboration will allow unprecedented access and ease of ordering/receiving test results to the more than 130 IVF centers who currently use eIVF in their practice.